AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Over the last 12 months, insiders at AbbVie Inc. have bought $0 and sold $93.32M worth of AbbVie Inc. stock.
On average, over the past 5 years, insiders at AbbVie Inc. have bought $19.8M and sold $72.69M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 750 shares for transaction amount of $51,750 was made by Durkin Brian L (VP, Controller) on 2020‑03‑30.
2024-03-20 | Sale | Donoghoe Nicholas | EVP, CHIEF BUS/STRAT OFFICER | 21,082 0.0012% | $176.30 | $3.72M | -5.68% | |
2024-03-18 | Sale | Stewart Jeffrey Ryan | EVP, CHIEF COMMERCIAL OFFICER | 58,949 0.0033% | $178.79 | $10.54M | -6.76% | |
2024-03-01 | Sale | RICHMOND TIMOTHY J. | EVP, CHIEF HR OFFICER | 75,680 0.0042% | $177.27 | $13.42M | -6.21% | |
2024-02-29 | Sale | Michael Robert A. | PRES & CHIEF OPERATING OFFICER | 68,879 0.0039% | $176.45 | $12.15M | -4.61% | |
2024-02-29 | Sale | Siatis Perry C | EVP, GC AND SECRETARY | 9,891 0.0006% | $177.39 | $1.75M | -4.61% | |
2024-02-29 | Sale | Buckbee Kevin K | SVP, CONTROLLER | 5,144 0.0003% | $176.65 | $908,688 | -4.61% | |
2024-02-28 | Sale | GONZALEZ RICHARD A | CHAIRMAN OF THE BOARD AND CEO | 138,616 0.0078% | $177.27 | $24.57M | -5.71% | |
2024-02-23 | Sale | Siatis Perry C | EVP, GC AND SECRETARY | 13,753 0.0008% | $177.51 | $2.44M | -5.53% | |
2024-02-23 | Sale | Reents Scott T | EVP, CHIEF FINANCIAL OFFICER | 14,140 0.0008% | $177.44 | $2.51M | -5.53% | |
2024-02-21 | Sale | SALEKI-GERHARDT AZITA | EVP, CHIEF OPERATIONS OFFICER | 52,870 0.003% | $173.71 | $9.18M | -3.75% | |
2023-12-26 | Sale | Donoghoe Nicholas | EVP, CHIEF BUS/STRAT OFFICER | 2,912 0.0002% | $154.72 | $450,545 | +8.39% | |
2023-08-01 | Sale | GONZALEZ RICHARD A | CHAIRMAN OF THE BOARD AND CEO | 60,000 0.0035% | $148.58 | $8.91M | +7.65% | |
2023-07-31 | Sale | GONZALEZ RICHARD A | CHAIRMAN OF THE BOARD AND CEO | 18,500 0.0011% | $149.15 | $2.76M | +6.71% | |
2023-04-25 | Sale | Sorg Elaine K. | SVP, US COMMERCIAL OPERATIONS | 6,130 0.0003% | $165.00 | $1.01M | -8.43% | |
2023-04-17 | Sale | Sorg Elaine K. | SVP, US COMMERCIAL OPERATIONS | 7,499 0.0004% | $161.67 | $1.21M | -6.32% | |
2023-04-03 | Sale | Sorg Elaine K. | 15,002 0.0008% | $160.03 | $2.4M | -5.03% | ||
2023-04-03 | Sale | Siatis Perry C | 3,520 0.0002% | $160.00 | $563,200 | -5.03% | ||
2023-03-13 | Sale | Stewart Jeffrey Ryan | 53,125 0.003% | $152.28 | $8.09M | +0.29% | ||
2023-03-01 | Sale | SALEKI-GERHARDT AZITA | 36,990 0.0021% | $154.48 | $5.71M | -2.01% | ||
2023-03-01 | Sale | Sorg Elaine K. | 15,003 0.0008% | $155.00 | $2.33M | -2.01% |
GONZALEZ RICHARD A | CHAIRMAN OF THE BOARD AND CEO | 519099 0.032% | $171.15 | 0 | 21 | |
SALEKI-GERHARDT AZITA | 243944 0.0108% | $171.15 | 0 | 19 | ||
Stewart Jeffrey Ryan | 60941 0.0035% | $171.15 | 1 | 8 | +37.99% | |
Donoghoe Nicholas | EVP, CHIEF BUS/STRAT OFFICER | 55903 0.0032% | $171.15 | 1 | 2 | +35.4% |
Michael Robert A. | Vice Chairman | 98645 0.0021% | $171.15 | 0 | 6 | |
RICHMOND TIMOTHY J. | 13837 0.0008% | $171.15 | 0 | 22 | ||
Siatis Perry C | 10397 0.0006% | $171.15 | 0 | 5 | ||
Buckbee Kevin K | SVP, CONTROLLER | 6983 0.0004% | $171.15 | 0 | 1 | |
Reents Scott T | 27065 0% | $171.15 | 0 | 3 | ||
Schumacher Laura J | Vice Chairman | 213003 0.0121% | $171.15 | 1 | 14 | +27.78% |
CHASE WILLIAM J | EVP, Finance & Administration | 169552 0.0096% | $171.15 | 1 | 7 | +28.08% |
SEVERINO MICHAEL | Vice Chairman | 152103 0.0086% | $171.15 | 0 | 7 | |
ALBAN CARLOS | Vice Chairman | 114899 0.0065% | $171.15 | 0 | 9 | |
LEONARD JOHN M. | SVP, Chief Scientific Officer | 107320 0.0061% | $171.15 | 0 | 2 | |
HURWICH THOMAS A. | VP, Controller | 67276 0.0038% | $171.15 | 0 | 7 | |
Gosebruch Henry O | EVP, Chief Strategy Officer | 41623 0.0024% | $171.15 | 1 | 6 | +30.67% |
TILTON GLENN F | director | 39735 0.0023% | $171.15 | 1 | 0 | <0.0001% |
Strom Carrie C | 37921 0.0021% | $171.15 | 0 | 4 | ||
Sorg Elaine K. | SVP, US COMMERCIAL OPERATIONS | 35330 0.002% | $171.15 | 0 | 10 | |
AUSTIN ROXANNE S | director | 34483 0.002% | $171.15 | 4 | 3 | +31.05% |
Durkin Brian L | VP, Controller | 19094 0.0011% | $171.15 | 3 | 3 | +36.78% |
RAPP EDWARD J | director | 2875 0.0002% | $171.15 | 5 | 0 | +17.9% |
WADDELL FREDERICK H | director | 2000 0.0001% | $171.15 | 1 | 0 | +22.15% |
The Vanguard Group | $31.03B | 9.65 | 170.38M | +6.22% | +$1.82B | 0.59 | |
BlackRock | $26.03B | 8.1 | 142.96M | -0.16% | -$40.72M | 0.59 | |
State Street | $14.2B | 4.42 | 77.97M | -0.29% | -$41.92M | 0.61 | |
JPMorgan Chase | $9.33B | 2.9 | 51.26M | -1.08% | -$102.03M | 0.84 | |
Capital International Investors | $8.76B | 2.72 | 48.1M | +6.91% | +$566.44M | 1.78 | |
Geode Capital Management | $6.81B | 2.12 | 37.49M | +1.29% | +$86.67M | 0.61 | |
Morgan Stanley | $6.4B | 1.99 | 35.17M | +3.29% | +$203.8M | 0.5 | |
Capital Research Global Investors | $5.7B | 1.77 | 31.3M | +3.27% | +$180.73M | 1.29 | |
Charles Schwab | $4.12B | 1.29 | 22.72M | -7.09% | -$314.45M | 0.93 | |
Northern Trust | $3.69B | 1.15 | 20.25M | -3.28% | -$124.89M | 0.62 | |
BNY Mellon | $3.61B | 1.12 | 19.83M | -10.28% | -$413.62M | 0.68 | |
Bank of America | $3.59B | 1.12 | 19.72M | +6.05% | +$204.79M | 0.35 | |
Legal & General | $2.76B | 0.86 | 15.14M | -0.46% | -$12.8M | 0.65 | |
Ameriprise Financial | $2.59B | 0.8 | 14.2M | +0.09% | +$2.2M | 0.72 | |
Fidelity Investments | $2.27B | 0.71 | 12.49M | +12.6% | +$254.53M | 0.15 | |
Franklin Templeton Investments | $2.03B | 0.63 | 11.15M | +47.23% | +$651.13M | 0.61 | |
Janus Henderson | $1.98B | 0.62 | 10.9M | +12.84% | +$225.87M | 1.08 | |
T. Rowe Price | $1.96B | 0.61 | 10.74M | +13.66% | +$235.13M | 0.24 | |
UBS | $1.91B | 0.6 | 10.51M | -3.64% | -$72.28M | 0.58 | |
Wells Fargo | $1.64B | 0.51 | 9.02M | -1.11% | -$18.38M | 0.44 | |
Goldman Sachs | $1.62B | 0.5 | 8.89M | -16.33% | -$315.88M | 0.31 | |
Nuveen | $1.62B | 0.5 | 8.89M | -2.42% | -$40.16M | 0.47 | |
Ubs Asset Management Americas Inc | $1.59B | 0.5 | 8.75M | -1.01% | -$16.21M | 0.57 | |
Massachusetts Financial Services Co Ma | $1.58B | 0.49 | 8.68M | +3.1% | +$47.52M | 0.47 | |
Deutsche Bank | $1.53B | 0.48 | 8.39M | +15.76% | +$207.92M | 0.7 | |
Royal Bank of Canada | $1.51B | 0.47 | 8.31M | -5.21% | -$83.17M | 0.36 | |
Dimensional Fund Advisors | $1.5B | 0.47 | 8.22M | +2.49% | +$36.3M | 0.4 | |
CalPERS | $1.22B | 0.38 | 6.68M | +9.83% | +$108.9M | 0.85 | |
Amundi | $1.04B | 0.36 | 6.3M | -21.05% | -$276.66M | 0.44 | |
State Farm | $1.09B | 0.34 | 5.99M | -3.39% | -$38.25M | 0.98 | |
Dz Bank Ag Deutsche Zentral Genossenschafts Bank Frankfurt Am Main | $1.05B | 0.33 | 5.78M | +66.36% | +$419.67M | 1.19 | |
Invesco | $968.45M | 0.3 | 5.32M | +0.95% | +$9.09M | 0.2 | |
Swiss National Bank | $962.82M | 0.3 | 5.29M | -4.2% | -$42.23M | 0.66 | |
AllianceBernstein | $891.42M | 0.28 | 4.9M | +16.73% | +$127.73M | 0.32 | |
T Rowe Price Investment Management Inc | $880.8M | 0.27 | 4.84M | -0.11% | -$955,297.45 | 0.54 | |
Envestnet Asset Management Inc | $850.36M | 0.26 | 4.67M | +2.18% | +$18.16M | 0.34 | |
HSBC | $849.59M | 0.26 | 4.67M | +12.8% | +$96.44M | 0.61 | |
PNC Financial Services | $806.4M | 0.25 | 4.43M | -6.38% | -$54.99M | 0.56 | |
Capital World Investors | $796.36M | 0.25 | 4.37M | +249.05% | +$568.21M | 0.13 | |
Sumitomo Mitsui Trust Holdings | $795.3M | 0.25 | 4.37M | -1.38% | -$11.12M | 0.55 | |
Raymond James Associates | $786.93M | 0.25 | 4.32M | -4.17% | -$34.23M | 0.53 | |
ClearBridge Investments | $756.58M | 0.24 | 4.15M | +5.38% | +$38.63M | 0.6 | |
Nordea Investment Management Ab | $745.73M | 0.23 | 4.11M | -6.59% | -$52.66M | 0.88 | |
Barclays | $691.12M | 0.22 | 3.8M | +16.32% | +$96.94M | 0.31 | |
Bank of Montreal | $653.04M | 0.21 | 3.62M | -8.39% | -$59.78M | 0.2 | |
Td Asset Management Inc | $632.62M | 0.2 | 3.47M | +156% | +$385.51M | 0.55 | |
First Trust | $609.82M | 0.19 | 3.35M | -13.52% | -$95.35M | 0.62 | |
Bahl & Gaynor Investment Counsel | $599.89M | 0.19 | 3.29M | -1.48% | -$9.04M | 3.34 | |
Robeco Institutional Asset Management B.V. | $596.21M | 0.19 | 3.27M | +50.67% | +$200.51M | 1.3 | |
RhumbLine Advisers | $592.83M | 0.18 | 3.26M | -0.83% | -$4.97M | 0.56 |